Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT – Get Free Report) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $0.05 and traded as high as $0.0523. Provectus Biopharmaceuticals shares last traded at $0.0523, with a volume of 250,800 shares.
Provectus Biopharmaceuticals Stock Up 5.0%
The firm’s fifty day simple moving average is $0.05 and its two-hundred day simple moving average is $0.06.
Provectus Biopharmaceuticals Company Profile
Provectus Biopharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing investigational therapies for cancer and immune-mediated diseases. The company’s research is based primarily on rose bengal, a small-molecule compound that it has formulated for potential use in oncology and dermatology.
Provectus’s lead product candidate is PV-10, an intralesional formulation of rose bengal being investigated for the treatment of solid tumors, including melanoma and certain liver cancers.
See Also
- Five stocks we like better than Provectus Biopharmaceuticals
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Provectus Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provectus Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
